Abstracts tagged "spondyloarthritis"

Abstract Number: 2209 • ACR Convergence 2023
Prevalence and Clinical Characteristics of Late Onset Axial Spondyloarthritis: Results from a Multicentre Nationwide Study
Margarida Lucas Rocha¹, Rita Torres², Sofia Ramiro³, Alice Morais Castro⁴, Alice Neves⁵, Ana Martins⁶, Ana Teodósio Chícharo¹, Beatriz Mendes⁷, Carolina Ochôa Matos⁸, Catarina Soares⁹, Cláudia Miguel¹⁰, Cláudia Pinto Oliveira¹¹, Hugo Parente¹², J. A. Melo Gomes¹³, Mariana Luís¹⁴, Mariana Santos¹⁵, Maura Couto¹⁶, Miguel Bernardes¹⁷, Paula Valente¹⁸, Roberto Costa¹⁹, Sandra Sousa⁴, Jaime Branco²⁰, Fernando Pimentel-Santos²¹ and Alexandre Sepriano²², ¹Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ²Hospital Egas Moniz, Lisboa, Portugal, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Departamento de Reumatologia, Hospital Garcia de Orta, Almada, Portugal, ⁵Instituto Português de Reumatologia, Lisboa, Portugal, ⁶Serviço de Reumatologia, Centro Hospitalar Universitário São João; Serviço de Medicina, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, ⁷Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁸Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁹Centro Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ¹²Serviço de Reumatologia do Centro Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal, ¹³Clínica Reumatológica Dr. Melo Gomes, Lisboa, Portugal, ¹⁴Serviço de Reumatologia – Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ¹⁵Serviço de Reumatologia do Centro Hospitalar Lisboa Ocidental, Hospital de Egas Moniz EPE, Lisboa, Portugal, ¹⁶Unidade de Reumatologia, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, ¹⁷Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, ¹⁸Serviço de Reumatologia, Centro Hospitalar Entre o Douro e o Vouga, Santa Maria da Feira, Portugal, ¹⁹Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ²⁰CHLO, EPE - Hospital Egas Moniz, Lisbon, Portugal, ²¹NOVA Medical School; Universidade NOVA e Lisboa, Lisboa, Portugal, ²²Leiden University Medical Centre, Portela Loures, Portugal
Background/Purpose: Axial spondyloarthritis (axSpA) typically starts before the fourth decade of life. Consistent with that, the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for…
Abstract Number: 2237 • ACR Convergence 2023
Upadacitinib in Refractory Psoriatic Arthritis. Multicenter Study of 134 Patients in Clinical Practice
Eva Galindez-Agirregoikoa¹, Diana Prieto-Peña², Maria Luz Garcia Vivar¹, Lucia Vega-Alvarez¹, Cristina Vergara³, Irati Urionaguena⁴, Consuelo Ramos-Giráldez⁵, Raquel Almodovar⁶, Beatriz Joven Ibáñez⁷, Rosario Garcia-Vicuna⁸, Vega Jovani⁹, Teresa González¹⁰, Àngels Martínez-Ferrer¹¹, Ana Urruticoechea Arana¹², Bryan Josue Flores Robles¹³, Cristina Campos Fernández¹⁴, Lilian Maria Lopez Nunez¹⁵, Joaquin Maria Belzunegui Otano¹⁶, Marina Pavia Pascual¹⁷, Esteban Rubio¹⁸, Angel Ramos-Calvo¹⁹, Noemi Busquets²⁰, Ana Pérez Gómez²¹, Francisco Miguel Ortiz Sanjuan²², Rafael Benito Melero-Gonzalez²³, Cristina Macía²⁴, María Ángeles Puche Larrubia²⁵, Jose Antonio Pinto Tasende²⁶, Cristina Fernandez²⁷, Maria Paz Martinez-Vidal²⁸, Jaime Calvo- Alén²⁹, Emma Beltran-Catalan³⁰, Mireia Moreno³¹, Silvia Pérez-Barrio³², iñigo Gorostiza Hormaeche¹ and Ricardo Blanco³³, ¹Basurto University Hospital, Bilbao, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Infanta Sofía, Madrid, Spain, ⁴GALDAKAO-USANSOLO UNIVERSITY HOSPITAL, GERNIKA-LUMO, Spain, ⁵Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, ⁶Alcorcón Foundation University Hospital, Madrid, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, ¹⁰Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹¹Hospital Universitario Dr Peset Valéncia, Valéncia, Spain, ¹²Hospital Can Misses, Ibiza, Spain, ¹³Hospital Universitario San Pedro, Logroño, Spain, ¹⁴Hospital General Universitario Valencia, Valencia, Spain, ¹⁵Son llatzer, Palmanyola, Spain, ¹⁶University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁷Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁸Servicio Andaluz Salud, Sevilla, Spain, ¹⁹Complejo Hospitalario de Soria, Soria, Spain, ²⁰HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ²¹Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ²²Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²³CHU Vigo, O Carballino, Spain, ²⁴Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁵Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ²⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²⁷Hospital Universitario San Juan de Alicante, Alicante, Spain, ²⁸Hospital Universitario San Juan Alicante, Alicante, Spain, ²⁹Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ³⁰HOSPITAL DEL MAR, Barcelona, Spain, ³¹Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ³²Hospital Universitario de Basurto, Bilbao, Spain, ³³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The EMA authorized Upadacitinib (UPA) in PsA in January 2021. UPA has shown efficacy in PsA refractory to anti-TNF in a clinical trial (RCT).…
Abstract Number: 0466 • ACR Convergence 2023
Impact of Postpartum on Patients with Inflammatory Rheumatic Diseases: The P2Rheum Study
Marie Hornez¹, Anna Molto², Maxime Leroy³, beatrice banneville⁴, Rakiba Belkhir⁵, elodie chauvet⁶, Marion Couderc⁷, Emanuelle Dernis⁸, sandra Desouches⁹, Valerie Devauchelle¹⁰, Aline Frazier-Mironer¹¹, Laure Gossec¹², elisabeth Gervais¹³, Hubert Marotte¹⁴, Christophe Richez¹⁵, Jeremie SELLAM¹⁶, Raphaele Seror¹⁷, Véronique Le Guern¹⁸, Gaelle Guettrot-Imbert¹⁸, Nathalie Costedoat-Chalumeau¹⁹, Rene-Marc Flipo²⁰ and Jean-Guillaume Letarouilly²¹, ¹University of Lille, Lille, France, ²HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ³CHU Lille - Department of Biostatistics, Lille, France, ⁴Sorbonne universite and Pitié Salpêtrière Hospital, la Garenne Colombes, France, ⁵Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France, ⁶CH Perpignan, Perpignan, France, ⁷CHU Gabriel Montpied, Clermont Ferrand, France, ⁸CH Le Mans, Le Mans, France, ⁹Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁰UBO, Brest, France, ¹¹APHP Lariboisiere Hospital, Paris, France, ¹²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ¹³CHU Poitiers, Poitiers, France, ¹⁴CHU Saint-Etienne, Saint-Etienne, France, ¹⁵Université de Bordeaux, Bordeaux, France, ¹⁶Sorbonne Université APHP, Paris, France, ¹⁷University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ¹⁸APHP Hôpital Cochin, Paris, France, ¹⁹Inserm DR Paris 5, Paris, France, ²⁰La Lettre du Rhumatologue, Paris, France, ²¹CHU Lille, Lille, France
Background/Purpose: There are limited data on the impact of the postpartum period (PP) on the activity of inflammatory rheumatic disorders (IRD), and the data available…
Abstract Number: 0526 • ACR Convergence 2023
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Maureen Dubreuil¹, Karl Gaffney², Jonathan Kay³, Victoria Navarro-Compán⁴, Christine de la Loge⁵, Alicia Ellis⁶, Carmen Fleurinck⁷, Ute Massow⁸, Vanessa Taieb⁹ and Atul Deodhar¹⁰, ¹Department of Rheumatology, Boston University School of Medicine, Milton, MA, ²Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ³Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Pharma, Oosterzele, Belgium, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹UCB Pharma, Colombes, France, ¹⁰Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…
Abstract Number: 0844 • ACR Convergence 2023
Facet Joint Inflammation Is Rare, but When Present It Is Associated with Facet Joint Ankylosis in Radiographic Axial Spondyloarthritis Patients from the SIAS Cohort
Manouk de Hooge¹, Rosalinde Stal², Alexandre Sepriano³, Xenofon Baraliakos⁴, Monique Reijnierse⁵, Juergen Braun⁶, Désirée van der Heijde⁷, Floris Van Gaalen² and Sofia Ramiro⁷, ¹Ghent University Hospital, Hesperange, Luxembourg, ²Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ³Leiden University Medical Centre, Portela Loures, Portugal, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: To assess whether posterior element (PE) inflammation, in particular in the facet joints (FJ), is associated with new facet joint ankylosis on MRI one…
Abstract Number: 1395 • ACR Convergence 2023
Aerobic Capacity and Its Relation to Disease Characteristics and Lifestyle Habits in Patients with Axial Spondyloarthritis
Elisabet Lindqvist¹, Johan Karlsson Wallman¹, Jonas Sagard², Tor Olofsson¹ and Elisabeth Mogard¹, ¹Lund University and Skåne University Hospital, Lund, Sweden, ²Skåne University Hospital, Lund, Sweden
Background/Purpose: Physical activity is part of the treatment of axial spondyloarthritis (axSpA), but despite this almost half of the patients do not meet the required…
Abstract Number: 1781 • ACR Convergence 2023
TNF Induces Neutrophil Elastase/Gasdermin D-mediated Neutrophil Extracellular Traps in Axial Spondyloarthritis
Yehao Li and Xiang Peng, Department of Rheumatology and Immunology, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Qingyuan, China
Background/Purpose: Emerging studies have shown that neutrophil extracellular traps (NETs) are increased and associated with the disease activity in patients with axial spondyloarthritis (axSpA). However,…
Abstract Number: 2077 • ACR Convergence 2023
A Curriculum of Online Education Significantly Improved Rheumatologists’ Knowledge, Competence and Confidence in Managing Patients with Spondyloarthritis
Elaine Bell¹, Marinella Calle² and Iain McInnes³, ¹Medscape Global Education, London, United Kingdom, ²MEDSCAPE GLOBAL, London, United Kingdom, ³University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are challenging conditions for rheumatologists to manage. There is an increasing focus on virtual training modalities post-pandemic.…
Abstract Number: 2210 • ACR Convergence 2023
Antibodies to Four Novel Peptides in New Onset Axial Spondyloarthritis
Pieter Ruytinx¹, Elien Luyten¹, Ann-Sophie De Craemer², Filip Van den Bosch³, Dirk Elewaut⁴ and Veerle Somers¹, ¹Biomedical Research Institute, Hasselt University, Department of Immunology and Infection, Diepenbeek, Belgium, ²Ghent University Hospital, Gent, Belgium, ³Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁴Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, an axSpA cDNA phage display library, constructed from…
Abstract Number: 2250 • ACR Convergence 2023
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies
Dafna Gladman¹, Laure Gossec², M. Elaine Husni³, Lars Erik⁴, Paolo Gisondi⁵, Alice B. Gottlieb⁶, Diamant Thaçi⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jérémy Lambert⁹, Nikos Lyris⁸, Jason Coarse¹⁰ and William R Tillett¹¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Università di Verona, Verona, Italy, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Irigny, France, ¹⁰UCB Pharma, Morrisville, NC, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: PsA has a substantial negative impact on patient (pt) health-related quality of life (HRQoL);1 symptom control, preventing structural damage, and normalizing physical and social…
Abstract Number: 0489 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Psoriatic Arthritis Treated with Secukinumab in Real World – Data from a German Observational Study
Asmir Vodencarevic¹, Jan Brandt-Juergens², Daniel Peterlik¹, Benjamin Gmeiner¹ and Uta Kiltz³, ¹Novartis Pharma GmbH, Nürnberg, Germany, ²rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients with psoriatic arthritis (PsA) in previous randomized clinical trials [1]. There is only limited…
Abstract Number: 0527 • ACR Convergence 2023
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
M. Elaine Husni¹, Philip J. Mease², Joseph Merola³, Frank Behrens⁴, Ennio G Favalli⁵, Dennis McGonagle⁶, William R Tillett⁷, Shigeyoshi Tsuji⁸, Barbara Ink⁹, Rajan Bajracharya⁹, Jérémy Lambert¹⁰, Jason Coarse¹¹ and Laure Gossec¹², ¹Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ³Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ⁴Goethe University, Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology, Frankfurt, Germany, ⁵ASST Gaetano Pini-CTO, University of Milan, Department of Rheumatology, Milan, Italy, ⁶Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ⁷Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Nippon Life Hospital, Osaka, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Irigny, France, ¹¹UCB Pharma, Morrisville, NC, ¹²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Pain and fatigue have been identified by patients (pts) as key features of PsA, driving the impact on their health-related quality of life.1 Bimekizumab…
Abstract Number: 0845 • ACR Convergence 2023
The Yield of Repeated Assessments in Chronic Back Pain Patients Suspected of Early Axial Spondyloarthritis: Two-year Data from the SPondyloArthritis Caught Early (SPACE) Cohort
Mary Lucy marques¹, Sofia Ramiro², Miranda Van Lunteren³, Rosalinde Stal³, Robert BM Landewé⁴, Marleen van de Sande⁵, Karen Minde Fagerli⁶, Inger Jorid Berg⁶, Maikel van oosterhout⁷, Sofia Exarchou⁸, Roberta Ramonda⁹, Désirée van der Heijde² and Floris Van Gaalen³, ¹Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ⁵Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ⁶Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁷Groene Hart Ziekenhuis, Gouda, Netherlands, ⁸Lund University, Åkarp, Sweden, ⁹University of Padova, Department of Rheumatology, Padova, Italy
Background/Purpose: We have shown in the SPACE cohort that a diagnosis of early axial Spondyloarthritis (axSpA) can be reliably made in patients with chronic back…
Abstract Number: 1397 • ACR Convergence 2023
Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compán¹, Lianne Gensler², Martin Rudwaleit³, Fabiana Ganz⁴, Shirley Chen⁴, Jayne Stigler⁴, Anna Schmagel⁴ and Xenofon Baraliakos⁵, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ³University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁴AbbVie, Inc., North Chicago, IL, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany
Background/Purpose: Upadacitinib 15 mg (UPA), an oral Janus kinase inhibitor, has shown efficacy and tolerability through 14 weeks in patients (pts) with active radiographic axial…
Abstract Number: 1782 • ACR Convergence 2023
The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
Jia (Sijia) Chen¹, Catherine Manning¹, Nataliya Yeremenko², Jae-Hyuck Shim³, Daniel Montoro⁴, Dominique Baeten⁵ and Ellen Gravallese⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴TenSixty Biosciences, Boston, MA, ⁵UCB Pharma, Slough, United Kingdom, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].